Introduction
============

Cardiac implantable electronic device (CIED) infection, is a major complication following implantation of these devices and represents a broad range of symptoms, varying from local complaints at the pulse generator pocket and/or the subcutaneous portion of the leads, to severe systemic manifestations ([@B23]; [@B21]; [@B8]). Accumulating evidence has suggested an increased rate of CIED infections worldwide due to continuous growth in the utilization of CIEDs ([@B4]; [@B27]; [@B14]). Data from the United States have indicated a 3.1-fold increase in the number of hospitalizations for CIED infection between 1996 and 2003 ([@B26]). Patients with CIED infection often have prolonged hospital stay, increased financial burden and higher rates of in-hospital morbidity and mortality. It has been shown that CIED infection increases the risk of in-hospital death by more than twofold ([@B26]). In addition, increased mortality persists even after hospital discharge ([@B8]), highlighting the need to maximize infection control measures in settings in which CIED infection is likely to occur.

*Staphylococcus* species, including coagulase-negative staphylococci (CoNS), methicillin-sensitive *Staphylococcus aureus* (MSSA), and methicillin-resistant *Staphylococcus aureus* (MRSA), are by far the most common microbiologic causes of CIED infections, accounting for 60%--80% of all CIED infections ([@B11]; [@B13]; [@B18]; [@B1]). However, unusual organisms, such as Gram-negative bacilli, are also present in CIED infections. The majority of CIED infections are pocket infections; however, when the infection moves to the intravascular portion of the leads, intravascular infection can occur, resulting in bacteremia and endocarditis. Interestingly, it was shown that the incidence of CIED infection in the setting of *S. aureus* bacteremia could reach 55% ([@B24]). In addition, Gram-negative and non-staphylococcal bacteremia can also cause CIED infection, although these infections are usually associated with lower morbidity and mortality ([@B25]). Therefore, an understanding of the microbiologic risk factors/microbial epidemiology of CIED infections is critical for the selection of both antimicrobial prophylaxis and initial empirical treatments, as the microbiology of CIED infections is closely associated with the pathogenesis of infection.

Two studies have recently described the asymptomatic bacterial colonization of CIEDs in China ([@B6]; [@B29]). However, there are limited data regarding the microbiological characteristics and clinical features of symptomatic CIED infections in China. It is of paramount importance to draw a basic picture of the characteristics of symptomatic CIED infections, as this information will provide valuable insights into the pathogenesis, implementation of preventive measures and treatment of CIED infections, especially when considering the rapid increase in methicillin-resistant *Staphylococcus* species in China ([@B28]).

Materials and Methods {#s1}
=====================

Patients and Case Definitions
-----------------------------

From November 2011 to November 2014, a total of 219 consecutive patients with sufficient evidence of CIED infection were included. Patients with CIED infections were defined as the presence of early post-implantation infections; generator pocket infections; constitutional symptoms or CIED-related lead infection or infectious endocarditis (CIED-LI/IE), as previously described ([@B5]; [@B19]). Specifically, an early post-implantation infection case was defined as erythema affecting the implantation incision site, without purulent exudate, exposed devices, or systemic signs of infection. Generator pocket infection was defined as the device penetrating through the skin or purulent exudate without systemic signs. Constitutional symptoms included positive blood cultures, and fever or chills without vegetation on the leads or cardiac valves. If vegetation was found by transesophageal echocardiography (TEE), a diagnosis of CIED-LI/IE was considered. Oral anticoagulant treatment was stopped before CIED-related procedures. The demographics and clinical characteristics of all patients with CIED infections are shown in **Table [1](#T1){ref-type="table"}**. Overall, patients with hypertension exhibited the highest prevalence of CIED infections (48.4%), followed by patients with diabetes mellitus (24.2%). The incidence of early post-implantation infections, generator pocket infections, constitutional symptoms, and CIED-LI/IE was 14.6% (32/219), 69.4% (152/219), 11.0% (24/219), and 5.0% (11/219), respectively. Positive cultures were identified in 145 patients with CIED infection (24 patients were positive for both blood culture and pocket tissue culture; 121 patients were positive for pocket tissue culture), accounting for 66.2% of all patients. The median length of stay was 15 days, and the in-hospital mortality was 0.9% (2/219). Study protocols were reviewed and approved by the Ethical Committee of Peking University People's Hospital. Informed consent was not needed as this study was retrospective and participants were anonymized.

###### 

Clinical information and demographics of patients with cardiac implantable electronic device (CIED) infection.

  --------------------------------------------------- ------------
  ***N* = 219**                                       
  Demographics                                        
      Median age at study (max, min), years           68 (58-77)
      Male, *n* (%)                                   161 (73.5)
      Median duration of infection (max, min), days   23 (10-37)
  Underlying diseases                                 
      Lung diseases, *n* (%)                          23 (10.5)
      Renal diseases, *n* (%)                         27 (12.3)
      Liver diseases, *n* (%)                         24 (11.0)
      Diabetes mellitus, *n* (%)                      53 (24.2)
      Hypertension, *n* (%)                           106 (48.4)
  Types of infection                                  
      Early post-implantation inflammation, *n* (%)   32 (14.6)
      Generator pocket infection, *n* (%)             152 (69.4)
      Constitutional symptoms, *n* (%)                24 (11.0)
      CIED-LI/IE^∗^, *n* (%)                          11 (5.0)
  Positive culture results                            
      Blood, *n* (%)                                  24 (11.0)
      Pocket tissue, *n* (%)                          145 (66.2)
  Treatment                                           
      Re-implantation, *n* (%)                        137 (62.6)
      Inappropriate empirical antimicrobial therapy   68 (31.1)
      Definitive antimicrobial therapy^∗∗^, *n* (%)   79 (36.1)
  Outcome                                             
      Median length of stay (max, min), days          15 (13-20)
      In-hospital death, *n* (%)                      2 (0.9)
                                                      
  --------------------------------------------------- ------------

∗

CIED-LI/IE, cardiac implantable electronic device associated lead infection or infectious endocarditis; CoNS, coagulase-negative staphylococci.

∗∗

Definitive antimicrobial therapy refers to the corrected therapy when microbiology results and antimicrobial susceptibility data were available.

Specimen Collection and Culture
-------------------------------

Pocket tissue was collected during device extraction. Each specimen (approximately 1 cm^3^ in size) was obtained using an aseptic technique. Pocket tissue samples for culture were placed in sterile bottles and transported to the clinical microbiology laboratory within 12 h. Samples were inoculated onto solid media (blood agar, eosin methylene blue agar, chocolate agar, and Sabouraud agar, Oxoid, Basingstoke, Hampshire, UK). Identification and antimicrobial susceptibility testing were performed using the Vitek 2 automated system (bioMérieux, Marcy-l'Etoile, France). Minimum inhibitory concentrations (MICs) were determined according to Clinical and Laboratory Standards Institute (CLSI) breakpoints ([@B7]; [@B17]).

Statistical Analysis
--------------------

The chi-squared or Fisher's exact test were used for categorical variables. Ordinal and continuous variables were presented as median (interquartile range) and determined by the Mann--Whitney *U* test. A *p*-value less than 0.05 was considered statistically significant. SPSS 19 (SPSS Inc., Chicago, IL, USA) statistical software was used for data analysis.

Results
=======

Comparison of Clinical Characteristics of CIED Infections between Patients with Primary Infections and Patients with Recurrent Infections
-----------------------------------------------------------------------------------------------------------------------------------------

Of all CIED infections, 112 cases were primary infections and 107 cases were recurrent infections (**Table [2](#T2){ref-type="table"}**). Importantly, the incidence of positive cultures from pocket tissue was significantly higher in patients with recurrent infections than in patients with primary infections (*p* = 0.020). A trend of higher incidence of positive cultures from blood was also observed in patients with recurrent infections than in patients with primary infections (*p* = 0.064). Cases for definitive antimicrobial therapy included 45.3% of patients with recurrent infections, which was significantly higher than that in patients with primary infections (*p* = 0.010). Interestingly, the only two cases of in-hospital mortality were observed in patients with recurrent infections. However, no significant difference was observed in the median length of stay between patients with primary infections and patients with recurrent infections (**Table [2](#T2){ref-type="table"}**).

###### 

Comparison of clinical characteristics and outcomes between primary and recurrent CIED infections.

  Characteristics                                                                   Primary infection (*N* = 112)   Recurrence (*N* = 107)   *p*
  --------------------------------------------------------------------------------- ------------------------------- ------------------------ ----------
  Infection features                                                                                                                         
  Median duration of infection occurrence after last procedure (max, min), months   24 (11.35--47)                  16 (6--36)               0.171
      Systemic infection, *n* (%)                                                   15 (13.4)                       21 (19.6)                0.213
  Positive culture results                                                                                                                   
      Pocket tissue, *n* (%)                                                        66 (58.9)                       79 (73.8)                0.020^∗^
      Blood, *n* (%)                                                                8 (8.4)                         16 (19.0)                0.064
  Treatment                                                                                                                                  
  Inappropriate empirical antimicrobial therapy, *n* (%)                            35 (32.1)                       33 (31.1)                0.877
  Definitive antimicrobial therapy, *n* (%)                                         31 (28.4)                       48 (45.3)                0.010^∗^
  Outcomes                                                                                                                                   
  Median length of stay (max, min), days                                            15 (13--19.75)                  15 (12--20)              0.916
  In-hospital death, *n* (%)                                                        0                               2 (1.9)                  0.146
                                                                                                                                             

∗

p

\< 0.05.

Comparison of Clinical Characteristics between Patients with Early CIED Infections and Patients with Late CIED Infections
-------------------------------------------------------------------------------------------------------------------------

Early CIED infection was defined as CIED infection occurring within 6 months of CIED-related procedures ([@B19]). Overall, 49 patients (22.4%) were identified as having early CIED infection and 170 patients (77.6%) were identified as having late CIED infection (**Table [3](#T3){ref-type="table"}**). In particular, patients with lung diseases were more likely to have early CIED infections (OR, 2.857; *p* = 0.016). In addition, patients with diabetes mellitus exhibited a trend of higher incidence of early infections compared to late infections (*p* = 0.052). No significant difference was observed in the median length of stay between patients with early CIED infections and patients with late CIED infections (**Table [3](#T3){ref-type="table"}**).

###### 

Comparison of clinical characteristics and outcomes between early and late CIED infections.

  Characteristics                          Early infection (≤6 months) (*N* = 49)   Late infection (\>6 months) (*N* = 170)   *p*     OR (95%CI)
  ---------------------------------------- ---------------------------------------- ----------------------------------------- ------- ---------------------
  Underlying diseases                                                                                                                 
      Lung diseases, *n* (%)               10 (20.4)                                14 (8.2)                                  0.016   2.857 (1.180-6.917)
      Renal diseases, *n* (%)              5 (10.2)                                 18 (10.6)                                 0.938   
      Liver diseases, *n* (%)              4 (8.2)                                  23 (13.5)                                 0.314   
      Diabetes mellitus, *n* (%)           17 (34.7)                                36 (21.2)                                 0.052   
      Hypertension, *n* (%)                25 (51.0)                                81 (47.6)                                 0.677   
  Positive test results                                                                                                               
      TEE^∗^, *n* (%)                      4 (8.2)                                  7 (4.1)                                   0.253   
      Blood culture, *n* (%)               8 (16.3)                                 16 (9.4)                                  0.107   
      Pocket tissue culture, *n* (%)       35 (71.4)                                110 (64.7)                                0.381   
  Outcomes                                                                                                                            
  Median length of stay (max, min), days   15 (12-19)                               15 (13-20)                                0.694   
  In-hospital death, *n* (%)               1 (2.0)                                  1 (0.6)                                   0.346   
                                                                                                                                      

∗

TEE, transesophageal echocardiography.

Comparison of Clinical Characteristics between Patients with Local CIED Infections and Patients with Systemic CIED Infections
-----------------------------------------------------------------------------------------------------------------------------

The differences in clinical characteristics between patients with local CIED infections and patients with systemic CIED infections were investigated (**Table [4](#T4){ref-type="table"}**). The results showed that patients with liver diseases were more susceptible to systemic infections than local infections (OR, 3.338; *p* = 0.012). In addition, a significantly higher rate of positive cultures from pocket tissue was observed in patients with systemic infections (*p* = 0.006). These patients consistently exhibited a higher rate of definitive antimicrobial therapy (*p* = 0.01). Moreover, the median length of stay was significantly longer in patients with systemic infections compared to patients with local infections (*p \<* 0.001).

###### 

Comparison of clinical characteristics, treatment and outcomes between local and systemic CIED infections.

  Characteristics                                              Local infection (*N* = 183)   Systemic infection (*N* = 36)   *p*          OR (95% CI)
  ------------------------------------------------------------ ----------------------------- ------------------------------- ------------ ----------------------
  Underlying diseases                                                                                                                     
      Lung diseases, *n* (%)                                   21 (11.5)                     3 (8.3)                         0.581        
      Renal diseases, *n* (%)                                  24 (13.1)                     3 (8.3)                         0.425        
      Liver diseases, *n* (%)                                  15 (8.2)                      8 (22.2)                        0.012ˆ\*     3.338 (1.292--8.626)
      Diabetes mellitus, *n* (%)                               44 (24.0)                     9 (25.0)                        0.903        
      Hypertension, *n* (%)                                    93 (50.8)                     13 (36.1)                       0.106        
  Positive pocket tissue culture, *n* (%)                      114 (62.3)                    31 (86.1)                       0.006ˆ\*     
  Treatment                                                                                                                               
      Inappropriate empirical antimicrobial therapy, *n* (%)   54 (30.2)                     14 (38.9)                       0.305        
      Definitive antimicrobial therapy, *n* (%)                59 (33.0)                     20 (55.6)                       0.010ˆ\*     
  Outcomes                                                                                                                                
      Median length of stay (max, min), days                   15 (12-18)                    20.5 (14.25-28)                 \<0.001ˆ\*   
  In-hospital death, *n* (%)                                   2 (1.1)                       0                               0.529        
                                                                                                                                          

∗

p

\< 0.05.

Microbiological Characteristics of CIED Infections
--------------------------------------------------

In all 145 cases who had a positive culture, 140 cases (96.6%) were monomicrobial infections, and the other five cases were polymicrobial infections (**Figure [1](#F1){ref-type="fig"}**). The polymicrobials identified in these five cases were *Pseudomonas aeruginosa* and *Klebsiella oxytoca*, *Staphyloccocus epidermidis* and *Staphyloccocus sciuri*, *S. epidermidis* and *Bacillus cereus*, *S. epidermidis* and *Sphingomonas paucimobilis*, and *Enterococcus faecalis* and *S. aureus*, respectively.

![**Pathogen distribution in patients with cardiac implantable electronic device (CIED) infections.** **(A)** Pocket tissue culture results of 219 patients with CEED infections. **(B)** Pathogen distribution in patients with primary and recurrent CIED infections. **(C)** Pathogen distribution in patients with local and systemic CIED infections. **(D)** Pathogen distribution in patients with early and late CIED infections.](fmicb-08-00360-g001){#F1}

Coagulase-negative staphylococci were the most frequently isolated pathogens, accounting for 45.2% of all cases, followed by non-fermentative bacilli (5.9%) and *S. aureus* (4.1%). Gram-negative bacilli were identified in 20 cases, accounting for 9.1% of all cases and 13.8% of culture-positive cases.

The distribution of different pathogens was determined between primary infections and recurrent infections, between local infections and systemic infections, and between early infections and late infections. Importantly, recurrent infections exhibited a higher prevalence of CoNS and non-fermentative bacilli, and a lower prevalence of negative culture and *Candida* compared to primary infections. In addition, non-fermentative bacilli were more easily detected in systemic infections than in local infections (16.7% vs. 3.8%). Furthermore, *S. aureus* was more likely to cause early infections than late infections (**Figure [1](#F1){ref-type="fig"}**).

*In vitro* Antimicrobial Susceptibility Testing
-----------------------------------------------

*In vitro* antimicrobial susceptibility testing was performed on all culture-positive pathogens. Generally, the prevalence of methicillin resistance among *S. aureus, S. epidermidis*, and remaining CoNS was 11.1, 66.2, and 44.0%, respectively. The resistance rates to erythromycin and clindamycin among these *Staphylococcus* species were 44.4%, 51.4% and 44.0%, 22.2%, 21.6%, and 12.0%, respectively. None of these *Staphylococcus* species were resistant to gentamicin, linezolid or vancomycin (**Table [5](#T5){ref-type="table"}**).

###### 

*In vitro* activities of antimicrobial agents against *Staphylococcus* sp..

  Antimicrobial agent   *Staphylococcus epidermidis* (*N* = 74)   *Staphylococcus aureus* (*N* = 9)   Remaining coagulase-negative staphylococci (*N* = 25)                                                                                 
  --------------------- ----------------------------------------- ----------------------------------- ------------------------------------------------------- ---- --------- ------ ------ ------ ------ --------- ------ ------ ------ --- ---------
  Oxacillin             66.2                                      0                                   4                                                       4    0.25--4   11.1   0      0.5    2      0.25--4   44.0   0      0.25   4   0.25--4
  Ciprofloxacin         40.5                                      12.2                                2                                                       8    0.5--8    0      11.1   0.5    0.5    0.5--2    8.0    0      0.5    4   0.5--8
  Levofloxacin          50.0                                      4.1                                 3                                                       8    0.12--8   0      0      0.25   0.25   0.12--1   8.0    16.0   0.25   2   0.12--4
  Rifampicin            8.1                                       0                                   0.5                                                     1    0.5--32   0      0      0.5    0.5    0.5       8.0    4.0    0.5    2   0.25--4
  Gentamicin            0                                         2.7                                 0.5                                                     4    0.5--8    0      0      0.5    1      0.5--1    0      4.0    0.5    2   0.5--8
  Tetracycline          16.2                                      4.1                                 2                                                       16   1--16     11.1   0      1      2      1--16     0      0      1      1   1--2
  Clindamycin           21.6                                      1.4                                 0.25                                                    8    0.25--8   22.2   0      0.25   8      0.25--8   12.0   4.0    0.25   8   0.25--8
  Erythromycin          51.4                                      2.7                                 8                                                       8    0.25--8   44.4   0      0.25   8      0.5--8    44.0   8.0    8      8   0.25--8
  Linezolid             0                                         0                                   1                                                       2    0.25--4   0      0      2      2      1--4      0      0      2      2   0.25--4
  Vancomycin            0                                         0                                   1                                                       2    0.5--4    0      0      0.5    1      0.5--1    0      0      1      2   0.5--2
                                                                                                                                                                                                                                            

MIC, minimum inhibitory concentration.

Comparison of Clinical Characteristics between Gram-Positive Infections and Gram-Negative Infections
----------------------------------------------------------------------------------------------------

The clinical characteristics between Gram-positive infections and Gram-negative infections were assessed (**Table [6](#T6){ref-type="table"}**). Of note, in comparison with patients infected by Gram-positive cocci, patients infected by Gram-negative bacilli showed a significantly higher incidence of exposed devices (50.0% vs. 23.2%), fever or chills (25.0% vs. 4.5%), and vegetation (20.0% vs. 5.4%). However, no significant difference in length of stay was noted between patients infected by Gram-positive cocci and patients infected by Gram-negative bacilli. The incidence of antimicrobial adjustment based on the culture results in patients infected by Gram-negative bacilli was 45.0%, which was significantly higher than that in patients infected by Gram-positive cocci (17.0%) (*p* = 0.005).

###### 

Comparison of clinical manifestations, treatment, and outcomes between Gram-positive and Gram-negative pathogens.

                                                     Gram-positive cocci (*N* = 112) (%)   Gram-negative bacilli (*N* = 20) (%)   *P*
  -------------------------------------------------- ------------------------------------- -------------------------------------- ----------
  Clinical symptoms                                                                                                               
      Purulent exudate, *n* (%)                      57 (50.9)                             8 (40.0)                               0.369
      Device exposure, *n* (%)                       26 (23.2)                             10 (50.0)                              0.013^∗^
      Fever or chills, *n* (%)                       5 (4.5)                               5 (25.0)                               0.001^∗^
      Vegetation, *n* (%)                            6 (5.4)                               4 (20.0)                               0.023^∗^
  Antimicrobial therapy                                                                                                           
      Median duration (max, min), days               13 (9--16)                            15.5 (10.5--18.75)                     0.174
      Adjustment based on culture results, *n* (%)   19 (17.0)                             9 (45.0)                               0.005^∗^
      Inappropriate empirical therapy, *n* (%)       52 (47.7)                             10 (50.0)                              0.850
  Outcomes                                                                                                                        
      Poor wound healing, *n* (%)                    5 (4.5)                               2 (10.0)                               0.309
      Fever or chills, *n* (%)                       16 (14.3)                             4 (20.0)                               0.511
      Median length of stay (max, min), days         15 (13--19)                           16.5 (14--22.5)                        0.199
      In-hospital death, *n* (%)                     0                                     0                                      --
                                                                                                                                  

∗

p

\< 0.05.

Discussion
==========

In this study, we comprehensively analyzed the microbiological characteristics and clinical features of CIED infections in China. To our knowledge, this is the first and the largest study regarding CIED infections in China. The major findings in this study are as follows: (1), patients with recurrent infections and patients with systemic infections tended to have higher rates of positive cultures from pocket tissue; (2), patients with lung diseases were more likely to have early CIED infections than late CIED infections; (3), patients with liver diseases were more susceptible to systemic infections than local infections; (4), *Staphylococcus* species were the most common cause of CIED infections with CoNS the predominant type; Gram-negative bacilli accounted for 9.1% of all cases and 13.8% of culture-positive cases; (5), significant differences in the distribution of different pathogens existed between primary infections and recurrent infections, between local infections and systemic infections, and between early infections and late infections; and 6), none of the *Staphylococcus* isolates were resistant to gentamicin, linezolid or vancomycin.

In this study, CoNS, which are part of the normal skin flora, were responsible for the majority of CIED infections (45.2% in all cases and 68.3% in culture-positive cases), indicating that most CIED infections were introduced at the time of implantation, as suggested by other studies ([@B3]; [@B10]; [@B15]). Interestingly, infections caused by *S. aureus* were only detected in 4.1% of all cases and in 6.2% of culture-positive cases. In addition, Gram-negative bacterial infections were identified in 9.1% of all cases and in 13.8% of culture-positive cases. A retrospective study of 189 cases of CIED infections at a single center in the United Stated revealed that CoNS and Gram-negative bacilli accounted for 42 and 9% of all infections, respectively, which were similar to our findings ([@B22]). However, in the United States study, *S. aureus* was responsible for another 29% of infections, which was much higher than that in our study (29% vs. 4.1%) ([@B22]). Of note, another study from Italy reported that CoNS, *S. aureus*, and Gram-negative bacilli were detected in 69.0, 13.8, and 6.2% of all culture-positive cases, respectively ([@B3]). In addition, a higher percentage of *S. aureus* was noted compared to our study (13.8% vs. 6.1%). The high percentage of CoNS and low percentage of *S. aureus* observed in our study may indicate the involvement of host- or device-specific factors that favor infection by CoNS over *S. aureus*. It has been demonstrated that CoNS, compared with *S. aureus*, are likely to be introduced onto device surfaces during insertion ([@B16]). In addition, CoNS have been shown to be more adept at evading the host innate immune system than *S. aureus* by being resistant to phagocytosis by neutrophils ([@B12]).

A number of associations between clinical characteristics and different types of CIED infections were identified in our study. Interestingly, previous studies have suggested that renal insufficiency and diabetes mellitus are important risk factors for CIED infections ([@B2]). In our study, we observed that 12.3 and 24.2% of patients with CIED infections had renal diseases and diabetes mellitus, respectively. In addition, patients with lung diseases were more likely to have early CIED infections. These data indicate that patients with these underlying conditions should be closely monitored after they receive a CIED. Moreover, we found that patients with liver diseases had a higher chance of systemic infections, suggesting that measures should be taken to avoid systemic infections in these patients.

As our study suggests that most CIED infections were introduced at the time of implantation, we recommend the use of antimicrobial prophylaxis which covers *Staphylococcus* species immediately before device insertion, as suggested by other studies ([@B9]; [@B20]). It is noteworthy that the majority of *S. epidermidis* isolates were resistant to methicillin. As *S. epidermidis* was the predominant pathogen causing CIED infections in our study, the clinical relevance of our findings indicate that vancomycin should be used as first-line empirical therapy, as suggested by other studies ([@B10]). In addition, based on our *in vitro* susceptibility test results, other antimicrobials, including rifampicin, gentamicin and linezolid, may be considered as alternatives for empirical therapy, particularly when vancomycin cannot be tolerated. However, it should be noted that when culture and *in vitro* susceptibility results become available, antimicrobial therapy should be adjusted accordingly.

In summary, our data describe the microbiological characteristics and clinical features of CIED infections, and provide evidence for advisory guidelines on the management of CIED infections in China.
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